Overview
No overview information available.
Background
No background information available.
Indication
用于缓解急、慢性鼻炎的鼻塞症状。
Associated Conditions
No associated conditions information available.
Clinical Trials
Title | Posted | Study ID | Phase | Status | Sponsor |
|---|
No clinical trials found
No clinical trials found for this drug
FDA Drug Approvals
Approved Product | Manufacturer | NDC Code | Route | Strength | Effective Date |
|---|---|---|---|---|---|
| No FDA approvals found for this drug. | |||||
EMA Drug Approvals
Approved Product | Authorization Holder | Status | Issued Date |
|---|---|---|---|
| No EMA approvals found for this drug. | |||
HSA Drug Approvals
Approved Product | Manufacturer | Approval Number | Dosage Form | Strength | Approval Date |
|---|---|---|---|---|---|
| No HSA approvals found for this drug. | |||||
NMPA Drug Approvals
Approved Product | Company | Approval Number | Drug Type | Dosage Form | Approval Date |
|---|---|---|---|---|---|
| Ephedrine Hydrichloride and Nitrofurazone Nasal Drops | 国药准字H32026126 | 化学药品 | 鼻用制剂 | 9/9/2020 | |
| Ephedrine Hydrichloride and Nitrofurazone Nasal Drops | 国药准字H35021294 | 化学药品 | 滴鼻剂 | 4/28/2020 | |
| Ephedrine Hydrichloride and Nitrofurazone Nasal Drops | 国药准字H32026507 | 化学药品 | 鼻用制剂 | 8/13/2020 | |
| Ephedrine Hydrichloride and Nitrofurazone Nasal Drops | 国药准字H32026071 | 化学药品 | 鼻用制剂 | 5/26/2021 | |
| Ephedrine Hydrichloride and Nitrofurazone Nasal Drops | 国药准字H13024243 | 化学药品 | 滴鼻剂 | 9/29/2020 | |
| Ephedrine Hydrichloride and Nitrofurazone Nasal Drops | 国药准字H31022695 | 化学药品 | 滴鼻剂 | 4/28/2020 | |
| Ephedrine Hydrichloride and Nitrofurazone Nasal Drops | 国药准字H42022546 | 化学药品 | 鼻用制剂(滴鼻剂) | 6/17/2020 |
PPB Drug Approvals
Approved Product | Registration No. | Company | Licence No. | Strength | Registration Date |
|---|---|---|---|---|---|
| No PPB approvals found for this drug. | |||||
TGA Drug Approvals
Approved Product | ARTG ID | Sponsor | Registration Type | Status | Registration Date |
|---|---|---|---|---|---|
| No TGA approvals found for this drug. | |||||